Publications by authors named "Philip Mease"

100Publications

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review.

Semin Arthritis Rheum 2020 Jun 18;50(5):1158-1181. Epub 2020 Jun 18.

Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2020.05.022DOI Listing
June 2020

GRAPPA 2019 Project Report.

J Rheumatol Suppl 2020 Jun;96:53-57

From the Duke University School of Medicine, Durham, North Carolina, USA; Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford; UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; University of Toronto and Women's College Hospital, Toronto, Ontario, Canada; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Bradford Hospitals UK NHS Foundation Trust, Bradford, UK; Duke-National University of Singapore (NUS) Medical School, Singapore; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; University of Alberta, Edmonton, Alberta, Canada; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; University of Copenhagen and National Hospital (Rigshospitalet), Copenhagen, Denmark; Our Lady's Hospice & Care Services, Dublin, Ireland; Charité-Universitätsmedizin Berlin, and German Rheumatism Research Centre, Berlin, Germany; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; University of Toronto, Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.200129DOI Listing
June 2020

The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates.

J Rheumatol Suppl 2020 Jun;96:46-49

From Duke-National University of Singapore (NUS) Medical School, Singapore, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Concord Repatriation General Hospital, Sydney, Australia; Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; Caduceus Biomedical Consulting LLC, Raleigh; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Double X Management Inc., Prosper, Texas; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; University of Toronto, Krembil Research Institute, and Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.200127DOI Listing
June 2020

Methotrexate in Psoriasis and Psoriatic Arthritis.

J Rheumatol Suppl 2020 Jun;96:31-35

From the Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts; Department of Pediatrics, Research Associate, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.200124DOI Listing
June 2020

Proceedings of the 2019 GRAPPA Collaborative Research Network Meeting.

J Rheumatol Suppl 2020 Jun;96:25-30

From the School of Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Krembil Research Institute, Toronto, Ontario, Canada; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Patient Research Partner, Our Lady's Hospice and Care Services, Dublin, Ireland; Swedish Medical Center/Providence-St. Joseph Health and University of Washington, Seattle, Washington, USA; University of Southern California, Los Angeles, California; University of Utah, Salt Lake City, Utah, USA; Bradford Hospitals NHS Foundation Trust, Bradford, UK; Amsterdam University Medical Centers/University of Amsterdam, Department of Clinical Immunology and Rheumatology Amsterdam, Infection & Immunity Institute, Amsterdam, the Netherlands; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Department of Rheumatology, St. Vincent's University Hospital Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.200123DOI Listing
June 2020

Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next Steps.

J Rheumatol Suppl 2020 Jun;96:11-18

From the Royal National Hospital for Rheumatic Diseases, University of Bath, Bath; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Duke-National University of Singapore (NUS) Medical School, Singapore; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; University of Toronto, Krembil Research Institute, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK; Rheumatic and Musculoskeletal Disease Unit, Our Lady's Hospice and Care Services, Dublin; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Chapel Allerton Hospital, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.200121DOI Listing
June 2020

Disease Characteristics, Quality of Life, and Work Productivity by Enthesitis Site: Real- World Data From the US Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

J Rheumatol 2020 Jun 1. Epub 2020 Jun 1.

From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Support for third-party writing assistance for this manuscript, furnished by Kheng Bekdache, PhD, of Health Interactions, Inc., was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Address correspondence to: Philip Mease MD, MACR, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.191117DOI Listing
June 2020

Evaluation of changes in skin and joint outcomes and associated treatment changes in PsA: Experience from the Corrona PsA/SpA Registry.

J Rheumatol 2020 May 1. Epub 2020 May 1.

Swedish-Providence-St. John Health Systems and University of Washington, Seattle, Washington, United States; Corrona, LLC, Waltham, Massachusetts, United States; Eli Lilly Company, Indianapolis, Indiana, United States; University of Southern California, Los Angeles, California, United States; New York School of Medicine, New York, New York, United States. Author Disclosures/Conflicts of Interest: Philip J. Mease: Research grants: Novartis, AbbVie, Amgen, BMS, Janssen, Eli Lilly, Novartis, Pfizer, SUN, UCB; Consultant fees: Abbvie, Amgen, BMS, Celgene, Corrona, Galapagos, Gilead, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, SUN, UCB; Speakers Bureau: AbbVie, Amgen, BMS, Genentech, Janssen, Eli Lilly, Novartis, Pfizer, UCB April Armstrong: Investigator, advisor and/or consultant to AbbVie, Janssen, Novartis, Eli Lilly and Company, Regeneron, Sanofi, Leo, Science 37, Modernizing Medicine, and Ortho Dermatologics. AbbVie, Janssen, Novartis, Eli Lilly and Company, Regeneron, Sanofi, Leo, Science 37, Modernizing Medicine, and Ortho Dermatologics. Address correspondence to Philip J. Mease, MD, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122. Email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190422DOI Listing
May 2020

Reply.

Arthritis Rheumatol 2020 07 28;72(7):1229-1230. Epub 2020 May 28.

Amgen Inc., Thousand Oaks, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.41273DOI Listing
July 2020

Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management.

Authors:
Philip Mease

Rheumatology (Oxford) 2020 Mar;59(Supplement_1):i21-i28

Rheumatology Division, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/keaa042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065458PMC
March 2020

Preface to the psoriatic arthritis supplement.

Authors:
Philip Mease

Rheumatology (Oxford) 2020 Mar;59(Supplement_1):i1-i3

University of Washington School of Medicine, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/keaa041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065455PMC
March 2020

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research.

Arthritis Res Ther 2020 02 3;22(1):18. Epub 2020 Feb 3.

Swedish Medical Center/Providence St. Joseph Health and University of Washington, 601 Broadway Suite 600, Seattle, WA, 98122, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-020-2103-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998345PMC
February 2020

Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis.

J Rheumatol 2020 Feb 1. Epub 2020 Feb 1.

From the Singapore General Hospital, Duke-NUS Medical School, Singapore; Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Concord Repatriation General Hospital, Sydney, Australia; Patient Research Partner, Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; Patient Research Partner, Hong Kong Psoriatic Arthritis Association, Hong Kong, China; National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Division of Rheumatology, University of Toronto, Krembil Research Institute, Toronto; Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the US National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503 Cores A and D, and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the US National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation. PH and RC (The Parker Institute, Bispebjerg and Frederiksberg Hospital) are supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). LCC is funded by a UK National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. AO is funded by the Rheumatology Research Foundation and NIH/NIAMS R01 AR072363. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, Department of Rheumatology and Immunology, Singapore General Hospital; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; P. Hojgaard, MD, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; R. Holland, MBBS, Concord Repatriation General Hospital; N. Goel, MD, Patient Research Partner, Adjunct Assistant Professor, Duke University School of Medicine; J. Chau, BBA, Patient Research Partner; L.C. Coates, MB ChB, PhD, NIHR Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, and the Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, The Academia, Level 4, 20 College Road, Singapore 169856. Email: Accepted for publication January 17, 2020.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.191119DOI Listing
February 2020

Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap.

Rheumatol Ther 2019 Dec 31;6(4):487-501. Epub 2019 Oct 31.

Swedish Medical Center and University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40744-019-00176-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858410PMC
December 2019

Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients.

J Rheumatol 2020 Jun 15;47(6):854-864. Epub 2019 Oct 15.

From the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; University of Glasgow, Glasgow; University of Oxford, Oxford, UK; Cleveland Clinic, Cleveland, Ohio, USA; Toronto Western Research Institute and University of Toronto, Toronto, Ontario, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190507DOI Listing
June 2020

Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population.

Patient Prefer Adherence 2019 13;13:1545-1556. Epub 2019 Sep 13.

Department of Internal Medicine and Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
https://www.dovepress.com/participation-in-an-innovative-pat
Publisher Site
http://dx.doi.org/10.2147/PPA.S215037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750846PMC
September 2019

Measurement properties of the minimal disease activity criteria for psoriatic arthritis.

RMD Open 2019 6;5(2):e001002. Epub 2019 Sep 6.

School of Medicine, Swedish Medical Center and University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2019-001002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744081PMC
April 2020

Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.

Rheumatol Ther 2019 Sep 28;6(3):435-450. Epub 2019 Jun 28.

NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40744-019-0165-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702662PMC
September 2019

Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis.

Authors:
Philip Mease

Curr Rheumatol Rep 2019 06 6;21(7):35. Epub 2019 Jun 6.

Rheumatology Research, Swedish Medical Center/Providence-St. Joseph Health, University of Washington School of Medicine, 601 Broadway Suite 600, Seattle, WA, 98122, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11926-019-0830-0DOI Listing
June 2019

Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials.

J Am Acad Dermatol 2020 Jan 1;82(1):54-61. Epub 2019 Jun 1.

Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.05.075DOI Listing
January 2020

GRAPPA 2018 Project Report.

J Rheumatol Suppl 2019 Jun;95:54-57

From Kezar Life Sciences, San Francisco, California; Duke University School of Medicine, Durham, North Carolina, USA; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; University of Toronto; Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; UK National Institute for Health Research (NIHR), Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of California at San Diego, La Jolla, California, USA; University of Alberta, Edmonton, Alberta, Canada; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington, USA; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190121DOI Listing
June 2019

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set.

J Rheumatol Suppl 2019 Jun;95:33-37

From the Duke-NUS Medical School, Singapore; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah; Kezar Life Sciences, San Francisco; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam, the Netherlands; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190122DOI Listing
June 2019

Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting.

J Rheumatol Suppl 2019 Jun;95:11-19

From the Rheumatology Research Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals NHS Foundation Trust, Bradford, UK; Department of Medicine, Division of Rheumatology, University of Toronto; Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Swedish Medical Center/Providence-St. Joseph Health, Seattle, Washington; University of Southern California, Los Angeles, California; University of Utah, Salt Lake City, Utah; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Conway Institute for Biomolecular Research, University College Dublin; Our Lady's Hospice and Care Services; Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Department of Medical Humanities, Amsterdam University Medical Center, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190118DOI Listing
June 2019

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.

Arthritis Res Ther 2019 05 10;21(1):118. Epub 2019 May 10.

Rheumatology Clinical Research Division, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1901-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509758PMC
May 2019

Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018.

J Rheumatol 2019 10 1;46(10):1355-1359. Epub 2019 Apr 1.

From the Department of Epidemiology and Biostatistics, Amsterdam University Medical Centre (VUmc); VUmc, Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam; Department of General Practice, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; Comprehensive Pain Center, University Hospital Carl Gustav Carus Dresden, Medical Faculty of the Technical University Dresden, Dresden, Germany; CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University, Cardiff; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds; Versus Arthritis, Patron Her Royal Highness The Duchess of Cornwall, Chesterfield; MRC North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Liverpool, UK; Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; The Rheumatology Research Unit, Department of Rheumatology, Odense University Hospital; Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark; Dragon Claw (Website for patients with rheumatic disease), New South Wales, Australia; Bingo and Fundraising Promotions, Mal Atwell Leisure Group, Willetton, Australia; SDG LLC, Cambridge, Massachusetts; Medicine Service, VA Medical Center; Departments of Medicine and Epidemiology at the Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, Alabama; Department of Anesthesiology and Pain Medicine, University of Washington; Rheumatology Research Swedish-Providence-St. Joseph Health Systems; University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181099DOI Listing
October 2019

Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis.

J Comp Eff Res 2019 05 26;8(7):497-510. Epub 2019 Feb 26.

CREATE Centre, Section of Rheumatology - Division of Infection & Immunity, Cardiff University School of Medicine, Tenovus Building, Heath Park Campus, Cardiff, CF14 4XN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer-2018-0141DOI Listing
May 2019

Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.

J Rheumatol 2019 08 15;46(8):996-1005. Epub 2019 Feb 15.

From the Division of Rheumatology, Department of Medicine, and the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Rheumatology, Duke University School of Medicine, Durham, North Carolina; Kezar Life Sciences, South San Francisco; Amgen Inc., Thousand Oaks, California; Swedish-Providence-St. John's Health Systems and University of Washington, Seattle, Washington; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore; University of Leeds, Leeds; University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases; University of Bath, Bath, UK; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; Department of Medicine, University of Toronto, Women's College Hospital; Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto; Cochrane Musculoskeletal Group, Ottawa Hospital Research Institute, Centre for Practice-Changing Research; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario; Pfizer Inc., Montreal, Quebec, Canada; Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; Department of Rheumatology, Odense University Hospital, Odense, Denmark; Department of Medical Humanities, Patient Research Partner, Amsterdam University Medical Centre, Amsterdam, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin, Ireland; Royal Prince Alfred Hospital Medical Centre, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776995PMC
August 2019

Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.

J Rheumatol 2019 05 15;46(5):475-482. Epub 2019 Jan 15.

From the University of Pennsylvania, Philadelphia, Pennsylvania; Corrona Research Foundation; New York University Hospital for Joint Diseases, New York, New York; University of Alabama at Birmingham, Birmingham, Alabama; University of Massachusetts, Worcester; Brigham and Women's Hospital, Boston, Massachusetts; University of California San Diego, San Diego, California; Albany Medical College, Albany, New York; Swedish Medical Center; University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.171034
Publisher Site
http://dx.doi.org/10.3899/jrheum.171034DOI Listing
May 2019

Ustekinumab Fails to Show Efficacy in a Phase III Axial Spondyloarthritis Program: The Importance of Negative Results.

Authors:
Philip Mease

Arthritis Rheumatol 2019 02 2;71(2):179-181. Epub 2019 Jan 2.

Swedish Medical Center and University of Washington Medical School, Seattle.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40759DOI Listing
February 2019

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

J Rheumatol 2019 08 15;46(8):990-995. Epub 2018 Dec 15.

From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore; Department of Medicine, Duke University School of Medicine, Durham, North Carolina; Kezar Life Sciences, South San Francisco; Division of Immunology, Stanford University, Palo Alto, California; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Global Patient Outcomes and Real World Evidence, Eli Lilly and Co., Indianapolis, Indiana; University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal Prince Alfred Hospital Medical Centre, Sydney, Australia; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Royal National Hospital for Rheumatic Diseases, Bath; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; Department of Rheumatology, Odense University Hospital, Odense, Denmark; Sorbonne Université; Rheumatology Department, Pitié Salpêtrière Hospital, AP-HP, Paris, France; VU Medical Centre, Amsterdam, the Netherlands; Global Medical Affairs, Pfizer Inc., Montreal, Quebec; Clinical Epidemiology Program, Ottawa Hospital Research Institute; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital and Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, Institute for Health Policy Management and Evaluation, University of Toronto; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571063PMC
August 2019

Classification and Outcome Measures for Psoriatic Arthritis.

Front Med (Lausanne) 2018 6;5:246. Epub 2018 Sep 6.

Division of Rheumatology and Krembil Research Institute, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2018.00246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135872PMC
September 2018

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.

Arthritis Care Res (Hoboken) 2019 03 12;71(3):367-378. Epub 2019 Feb 12.

University of Queensland Brisbane, Rheumatology Research Unit Sunshine Coast, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/acr.23738
Publisher Site
http://dx.doi.org/10.1002/acr.23738DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593968PMC
March 2019

Functional impairment measurement in psoriatic arthritis: Importance and challenges.

Semin Arthritis Rheum 2018 12 23;48(3):436-448. Epub 2018 May 23.

University of Toronto and Toronto Western Hospital, 399 Bathurst Street 1E-410B, Toronto, ON, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2018.05.010DOI Listing
December 2018

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

J Rheumatol 2018 10 1;45(10):1389-1396. Epub 2018 Jul 1.

From the Swedish Medical Center and University of Washington, Seattle, Washington; Novartis Pharmaceuticals Corp., East Hanover, New Jersey; Corrona LLC, Waltham, Massachusetts; University of California San Diego, La Jolla, California; Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester; New York University School of Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.171094DOI Listing
October 2018

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Rheumatology (Oxford) 2018 10;57(10):1777-1788

Division of Rheumatology, Department of Medicine, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152421PMC
October 2018

Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study.

J Rheumatol 2018 08 15;45(9):1256-1262. Epub 2018 Jun 15.

From the Department of Medical Sciences, Policlinico of the University of Cagliari; Rheumatology Unit, and Department of Public Health, University of Cagliari, Cagliari; Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Matera; Rheumatology Research Unit, Department of Clinical and Experimental Medicine, University "Federico II," Naples; Department of Rheumatology, ASST Gaetano Pini-Centro Traumatologico Ortopedico (CTO), Milan; Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Modena and Reggio Emilia; Dipartimento di Medicina e Scienze della Salute, Università degli Studi del Molise, Campobasso, Italy; University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Academic Medical Center/University of Amsterdam; Amsterdam Rheumatology and Immunology Center Reade, Amsterdam, the Netherlands; Rehabilitation Teaching and Research Unit, Department of Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand; Medizinische Klinik III mit Poliklinik, Friedrich-Alexander-Universität Erlangen-Nuernberg, Erlangen, Germany; Sector of Dermatology, HUCFF School of Medicine, Federal University of Rio de Janeiro and Sector of Dermatology, HUPE School of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil; Spondyloarthritis Program, Johns Hopkins University, School of Medicine, Baltimore, Maryland; Swedish Medical Centre and University of Washington School of Medicine, Seattle, Washington, USA; Department of Rheumatology, Semmelweis University, Budapest, Hungary; Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.171183DOI Listing
August 2018

GRAPPA 2017 Project Report.

J Rheumatol Suppl 2018 Jun;94:48-51

From the University of Utah, Salt Lake City, Utah; University of California at San Diego, La Jolla, California; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; New York University School of Medicine, New York; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180139DOI Listing
June 2018

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database.

J Rheumatol Suppl 2018 Jun;94:26-29

From the University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Orthopedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford; Department of Rheumatology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge; Royal National Hospital for Rheumatic Diseases; University of Bath, Bath, UK; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Department of Rheumatology, Erasmus Medical Center, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180132DOI Listing
June 2018

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

J Rheumatol Suppl 2018 Jun;94:17-25

From the Royal Prince Alfred Hospital Medical Centre, Sydney, Australia; Royal National Hospital for Rheumatic Diseases, Bath, UK; University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; University of Toronto, Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; University of Oxford, Oxford, UK; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, USA; Department of Rheumatology, St. Vincents University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; VU Medical Centre, Amsterdam, the Netherlands; IQVIA, Duke University School of Medicine, Durham, North Carolina, USA; School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180142DOI Listing
June 2018

Considerations for the definition of remission criteria in psoriatic arthritis.

Semin Arthritis Rheum 2018 06 31;47(6):786-796. Epub 2017 Oct 31.

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2017.10.021DOI Listing
June 2018

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis.

J Am Acad Dermatol 2018 Sep 17;79(3):593-595. Epub 2018 Mar 17.

Department of Rheumatology Research, Swedish-Providence-St. Joseph Health Systems and University of Washington School of Medicine, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.03.008DOI Listing
September 2018

Tofacitinib for Psoriatic Arthritis.

N Engl J Med 2018 02;378(8):775-776

University of Toronto, Toronto, ON, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1715189DOI Listing
February 2018